A Phase I/II Open-label, Single-arm, Multi-center Study of Ruxolitinib Added to Corticosteroids in Pediatric Patients With Grade II-IV Acute Graft vs. Host Disease After Allogeneic Hematopoietic Stem Cell Transplantation
Phase of Trial: Phase I/II
Latest Information Update: 16 Nov 2019
Price : $35 *
At a glance
- Drugs Ruxolitinib (Primary) ; Calcineurin inhibitors; Corticosteroids
- Indications Graft-versus-host disease
- Focus Pharmacokinetics; Therapeutic Use
- Sponsors Novartis Pharma A.G.; Novartis Pharmaceuticals
- 10 Nov 2019 Planned number of patients changed from 54 to 55.
- 12 Jul 2019 Planned number of patients changed from 45 to 54.
- 21 May 2019 Planned End Date changed from 1 Jul 2022 to 2 Jun 2023.